|Bid||201.38 x 1000|
|Ask||201.43 x 900|
|Day's range||198.02 - 204.68|
|52-week range||117.06 - 204.68|
|Beta (5Y monthly)||0.37|
|PE ratio (TTM)||33.05|
|Earnings date||29 Jan 2021|
|Forward dividend & yield||3.40 (1.69%)|
|Ex-dividend date||11 Feb 2021|
|1y target est||194.47|
Results of a clinical trial suggest pre-emptive treatment with bamlanivimab can prevent COVID-19 from spreading through nursing homes.
The FDA accepts Precision BioSciences' (DTIL) regulatory application to initiate a clinical study on its next-generation CD19 product candidate, PBCAR19B.
Eli Lilly (LLY) signs a deal with Merus to develop novel T-cell re-directing bispecific antibodies. While Merus will lead early-stage development, Loxo Oncology will take care of further development and commercialization.